Silk Road Medical (SILK) Stock Price, News & Analysis

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 1 year target prices for Silk Road Medical's shares. Their SILK share price targets range from $8.00 to $47.00. On average, they expect the company's stock price to reach $22.18 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price.
View analysts price targets for SILK or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $12.27 at the beginning of 2024. Since then, SILK shares have increased by 41.8% and is now trading at $17.40.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our SILK earnings forecast.

Silk Road Medical will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Silk Road Medical, Inc (NASDAQ:SILK) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.07. The business had revenue of $47.27 million for the quarter, compared to analysts' expectations of $42.23 million. Silk Road Medical had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 31.70%.

ETFs with the largest weight of Silk Road Medical (NASDAQ:SILK) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and American Century Focused Dynamic Growth ETF (FDG).iShares U.S. Medical Devices ETF (IHI).

Silk Road Medical updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $194.0 million-$198.0 million, compared to the consensus revenue estimate of $191.7 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include RTX (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

Silk Road Medical (SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (11.62%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Kevin J Ballinger, Kevin M Klemz, Lucas W Buchanan, Marie L Jones, Richard Ruedy and Tony M Chou.
View institutional ownership trends.

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.